6/08

Since Alzhemed's failure to meet the significance expected in its trials, the followup data analyses have not indicated the Alzhemed works.

10/03

The Neurochem Company reports the following concerning it's new Alzheimer's Disease drug called Alzhemed™ now in clinicl trials :

Alzhemed™ has completed a Phase II clinical trial. A phase 3 trial is under way (it might even be available to mild AD patients now - 1/05)

Neurochem had previously investigated the safety, tolerability and pharmacokinetic profiles of Alzhemed™ in healthy volunteers in the four Phase I clinical trials. In in vivo studies, its anti-amyloid effectiveness has also been evaluated in a transgenic mouse model of brain amyloid and demonstrated that Neurochem's compound had a dose-dependent inhibitory effect on both the development of cerebro-vascular amyloid ß (Aß) deposition and on Aß plasma concentration.

Results of the phase I clinical studies, presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer's Therapy in 2002, and other interesting information is available upon request from the company.

As part of a unique "disease modifying" class of drug candidates developed by Neurochem, Alzhemed™ is believed to act at three levels:

To prevent and stop the formation and deposition of amyloid fibrils in the brain and in binding to soluble Aß - prior to fibril formation;

To favor the clearance of soluble Aß from the brain, lowering the risk of fibril formation; and

To inhibit the inflammatory response associated with amyloid build-up in Alzheimer's Disease.

AlzheimersScreen.com comment: You might want to investigate the status of other "amyloid aggregation-inhibitors" e.g. Praecis and Serono companies.